AU Patent

AU2009213751B2 — Treatment of metastatic stage prostate cancer with degarelix

Assigned to Ferring International Center SA · Expires 2014-09-25 · 12y expired

What this patent protects

Compositions comprising degarelix for the treatment of metastatic stage prostate cancer in a subject are provided.

USPTO Abstract

Compositions comprising degarelix for the treatment of metastatic stage prostate cancer in a subject are provided.

Drugs covered by this patent

Patent Metadata

Patent number
AU2009213751B2
Jurisdiction
AU
Classification
—
Expires
2014-09-25
Drug substance claim
No
Drug product claim
No
Assignee
Ferring International Center SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.